Fruquintinib CAS 1194506-26-7

Product Name: fruquintinib CAS 1194506-26-7

 

6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide;

 

Appearance: white to off-white powder

Assay: Greater than or equal to 99.0%

Boiling point: 600.5 degree (Predicted)

Density: 1.302g/cm3

Solubility: Soluble in DMSO (up to 5 mg/ml).

 

 

Fruquintinib (HMPL-013) is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor. It was approved by the FDA on 8 November 2023 for the treatment of adult patients with metastatic colorectal cancer. and these patients had previously received fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, anti-vascular endothelial growth factor therapy, and anti-epidermal growth factor receptor (EGFR) therapy. Fruquintinib has also been shown to improve cognitive deficits and pathological changes in a mouse model of cerebral amyloid angiopathy (CAA).

 

 

Popularni tagovi: fruquintinib cas 1194506-26-7, manufacturers, suppliers, factory, buy, in stock

• Par: Elinzanetant CAS 929046-33-3
• Sljedeći: Survodutide CAS 2805997-46-8